vs

Side-by-side financial comparison of HARTE HANKS INC (HHS) and InfuSystem Holdings, Inc (INFU). Click either name above to swap in a different company.

HARTE HANKS INC is the larger business by last-quarter revenue ($39.9M vs $36.2M, roughly 1.1× InfuSystem Holdings, Inc). On growth, InfuSystem Holdings, Inc posted the faster year-over-year revenue change (7.0% vs -15.4%). InfuSystem Holdings, Inc produced more free cash flow last quarter ($7.0M vs $-686.0K). Over the past eight quarters, InfuSystem Holdings, Inc's revenue compounded faster (6.4% CAGR vs -6.4%).

Harte Hanks is a global marketing services company headquartered in Boston, Massachusetts. Harte Hanks services include analytics, strategy, marketing technology, creative services, digital marketing, customer care, direct mail, logistics, and fulfillment.

InfuSystem Holdings, Inc. is a U.S.-headquartered healthcare provider specializing in infusion therapy solutions. It supplies programmable infusion pumps, matching disposable medical consumables, and professional clinical support services, serving oncology clinics, home healthcare providers, and acute care facilities across North America.

HHS vs INFU — Head-to-Head

Bigger by revenue
HHS
HHS
1.1× larger
HHS
$39.9M
$36.2M
INFU
Growing faster (revenue YoY)
INFU
INFU
+22.5% gap
INFU
7.0%
-15.4%
HHS
More free cash flow
INFU
INFU
$7.7M more FCF
INFU
$7.0M
$-686.0K
HHS
Faster 2-yr revenue CAGR
INFU
INFU
Annualised
INFU
6.4%
-6.4%
HHS

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
HHS
HHS
INFU
INFU
Revenue
$39.9M
$36.2M
Net Profit
$2.2M
Gross Margin
56.4%
Operating Margin
-0.3%
10.3%
Net Margin
5.5%
Revenue YoY
-15.4%
7.0%
Net Profit YoY
EPS (diluted)
$0.30
$0.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
HHS
HHS
INFU
INFU
Q4 25
$39.9M
$36.2M
Q3 25
$39.5M
$36.5M
Q2 25
$38.6M
$36.0M
Q1 25
$41.6M
$34.7M
Q4 24
$47.1M
$33.8M
Q3 24
$47.6M
$35.3M
Q2 24
$45.0M
$33.7M
Q1 24
$45.4M
$32.0M
Net Profit
HHS
HHS
INFU
INFU
Q4 25
$2.2M
Q3 25
$-2.3M
$2.3M
Q2 25
$-335.0K
$2.6M
Q1 25
$-392.0K
$-267.0K
Q4 24
Q3 24
$142.0K
$1.8M
Q2 24
$-27.8M
$717.0K
Q1 24
$-171.0K
$-1.1M
Gross Margin
HHS
HHS
INFU
INFU
Q4 25
56.4%
Q3 25
57.1%
Q2 25
55.2%
Q1 25
55.2%
Q4 24
53.8%
Q3 24
53.9%
Q2 24
49.5%
Q1 24
51.5%
Operating Margin
HHS
HHS
INFU
INFU
Q4 25
-0.3%
10.3%
Q3 25
1.3%
10.4%
Q2 25
0.1%
10.5%
Q1 25
-0.1%
1.8%
Q4 24
-3.3%
7.7%
Q3 24
4.0%
9.2%
Q2 24
3.0%
5.5%
Q1 24
0.8%
-2.6%
Net Margin
HHS
HHS
INFU
INFU
Q4 25
5.5%
Q3 25
-5.8%
6.2%
Q2 25
-0.9%
7.2%
Q1 25
-0.9%
-0.8%
Q4 24
Q3 24
0.3%
5.1%
Q2 24
-61.8%
2.1%
Q1 24
-0.4%
-3.5%
EPS (diluted)
HHS
HHS
INFU
INFU
Q4 25
$0.30
$0.09
Q3 25
$-0.31
$0.11
Q2 25
$-0.05
$0.12
Q1 25
$-0.05
$-0.01
Q4 24
$-0.31
$0.05
Q3 24
$0.02
$0.08
Q2 24
$-3.84
$0.03
Q1 24
$-0.02
$-0.05

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
HHS
HHS
INFU
INFU
Cash + ST InvestmentsLiquidity on hand
$5.6M
$3.2M
Total DebtLower is stronger
$19.6M
Stockholders' EquityBook value
$20.5M
$57.3M
Total Assets
$91.8M
$100.6M
Debt / EquityLower = less leverage
0.34×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
HHS
HHS
INFU
INFU
Q4 25
$5.6M
$3.2M
Q3 25
$6.5M
$955.0K
Q2 25
$4.8M
$720.0K
Q1 25
$9.0M
$1.5M
Q4 24
$9.8M
$527.0K
Q3 24
$5.9M
$380.0K
Q2 24
$11.0M
$146.0K
Q1 24
$11.5M
$822.0K
Total Debt
HHS
HHS
INFU
INFU
Q4 25
$19.6M
Q3 25
$20.9M
Q2 25
$26.3M
Q1 25
$28.7M
Q4 24
$23.9M
Q3 24
$28.0M
Q2 24
$34.2M
Q1 24
$29.9M
Stockholders' Equity
HHS
HHS
INFU
INFU
Q4 25
$20.5M
$57.3M
Q3 25
$19.9M
$55.5M
Q2 25
$22.2M
$54.5M
Q1 25
$21.4M
$55.1M
Q4 24
$21.7M
$57.5M
Q3 24
$21.0M
$55.5M
Q2 24
$20.6M
$53.5M
Q1 24
$20.0M
$52.3M
Total Assets
HHS
HHS
INFU
INFU
Q4 25
$91.8M
$100.6M
Q3 25
$92.7M
$98.9M
Q2 25
$95.0M
$100.8M
Q1 25
$100.6M
$104.3M
Q4 24
$101.8M
$103.6M
Q3 24
$108.1M
$105.3M
Q2 24
$109.7M
$108.5M
Q1 24
$113.4M
$104.8M
Debt / Equity
HHS
HHS
INFU
INFU
Q4 25
0.34×
Q3 25
0.38×
Q2 25
0.48×
Q1 25
0.52×
Q4 24
0.41×
Q3 24
0.50×
Q2 24
0.64×
Q1 24
0.57×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
HHS
HHS
INFU
INFU
Operating Cash FlowLast quarter
$737.0K
$7.1M
Free Cash FlowOCF − Capex
$-686.0K
$7.0M
FCF MarginFCF / Revenue
-1.7%
19.3%
Capex IntensityCapex / Revenue
3.6%
0.4%
Cash ConversionOCF / Net Profit
0.33×
TTM Free Cash FlowTrailing 4 quarters
$-4.5M
$23.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
HHS
HHS
INFU
INFU
Q4 25
$737.0K
$7.1M
Q3 25
$3.2M
$8.5M
Q2 25
$-4.8M
$7.0M
Q1 25
$-818.0K
$1.8M
Q4 24
$4.0M
$7.9M
Q3 24
$-2.9M
$9.8M
Q2 24
$1.6M
$2.3M
Q1 24
$-5.7M
$377.0K
Free Cash Flow
HHS
HHS
INFU
INFU
Q4 25
$-686.0K
$7.0M
Q3 25
$2.2M
$8.4M
Q2 25
$-5.1M
$6.8M
Q1 25
$-923.0K
$1.6M
Q4 24
$3.4M
$7.4M
Q3 24
$-4.9M
$9.8M
Q2 24
$926.0K
$2.0M
Q1 24
$-6.2M
$195.0K
FCF Margin
HHS
HHS
INFU
INFU
Q4 25
-1.7%
19.3%
Q3 25
5.5%
23.1%
Q2 25
-13.1%
18.9%
Q1 25
-2.2%
4.7%
Q4 24
7.3%
21.9%
Q3 24
-10.2%
27.7%
Q2 24
2.1%
5.9%
Q1 24
-13.7%
0.6%
Capex Intensity
HHS
HHS
INFU
INFU
Q4 25
3.6%
0.4%
Q3 25
2.5%
0.2%
Q2 25
0.6%
0.6%
Q1 25
0.3%
0.4%
Q4 24
1.3%
1.6%
Q3 24
4.0%
0.1%
Q2 24
1.5%
1.0%
Q1 24
1.2%
0.6%
Cash Conversion
HHS
HHS
INFU
INFU
Q4 25
0.33×
Q3 25
3.76×
Q2 25
2.70×
Q1 25
Q4 24
Q3 24
-20.76×
5.45×
Q2 24
3.22×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

HHS
HHS

Fulfillment And Logistics Services$17.3M43%
Customer Care$13.7M34%
Other$8.9M22%

INFU
INFU

Patient Services$20.0M55%
Device Solutions$14.4M40%
Other$1.9M5%

Related Comparisons